| Severe Combined Immunodeficiency

Flebogamma DIF 5% vs Octagam 5%

Side-by-side clinical, coverage, and cost comparison for severe combined immunodeficiency.

Deep comparison between: Flebogamma vs Octagam Immune Globulin (Human) with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsOctagam Immune Globulin (Human) has a higher rate of injection site reactions vs Flebogamma based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Octagam Immune Globulin (Human) but not Flebogamma, including UnitedHealthcare

Category

Flebogamma

Octagam Immune Globulin (Human)

At A Glance

RouteIV infusion

FrequencyEvery 3-4 weeks

ClassImmune globulin (IGIV)

RouteIV infusion

FrequencyEvery 3-4 weeks

ClassIntravenous immunoglobulin (IVIG)

Indications

Common Variable Immunodeficiency
X-linked agammaglobulinemia
Severe Combined Immunodeficiency
Wiskott-Aldrich Syndrome

Congenital agammaglobulinemia
Common Variable Immunodeficiency
X-linked agammaglobulinemia
Wiskott-Aldrich Syndrome
Severe Combined Immunodeficiency

Dosing

Common Variable Immunodeficiency, X-linked agammaglobulinemia, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome 300-600 mg per kg body weight IV every 3-4 weeks; initial infusion rate 0.01 mL/kg/min (0.5 mg/kg/min), increased to maximum 0.10 mL/kg/min (5 mg/kg/min) if tolerated.

Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300-600 mg/kg IV every 3-4 weeks; adjust dose over time to achieve desired trough levels and clinical response.

Measles Exposure 400 mg/kg IV as soon as possible and within 6 days of exposure; increase to at least 530 mg/kg every 3-4 weeks if patient is at risk of future measles exposure.

Contraindications

History of anaphylactic or severe systemic hypersensitivity reactions to human immune globulin
IgA-deficient patients with antibodies to IgA and a history of hypersensitivity

Acute severe hypersensitivity reaction to human immunoglobulin
IgA deficiency with antibodies against IgA and history of hypersensitivity
Acute hypersensitivity reaction to corn (product contains maltose derived from corn)

Drug Interactions

163View drug interactions

Adverse Reactions

Most common, adults (>=5%) Headache, pyrexia, pain, injection site reactions, diarrhea, rigors, urticaria, infusion site inflammation

Most common, pediatrics (>=5%) Headache, pyrexia, hypotension, tachycardia, diastolic hypotension, nausea, abdominal pain, diarrhea, pain, vomiting

Postmarketing Hypersensitivity/anaphylaxis, acute renal dysfunction/failure, ARDS, TRALI, cardiac arrest, thromboembolism, coma, seizures, aseptic meningitis syndrome, Stevens-Johnson Syndrome, pancytopenia, hemolysis

Most common (>=5%) headache, nausea

Serious anaphylactic reactions, thromboembolic events, aseptic meningitis, hemolytic anemia

Postmarketing leukopenia, hemolytic anemia, anaphylactic shock, angioedema, cerebrovascular accident, myocardial infarction, pulmonary embolism, renal failure acute, transfusion-related acute lung injury

Pharmacology

Flebogamma 5% DIF is an intravenous immune globulin (IGIV) that provides replacement therapy for primary immunodeficiency by supplying a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents.

Intravenous immunoglobulin G preparation that supplies a broad spectrum of opsonic and neutralizing IgG antibodies against bacteria and their toxins; restores abnormally low IgG levels to the normal range in patients with primary humoral immunodeficiency.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Flebogamma